By Digifin Pty Ltd · About this coverage
Key Points
- Initial drawdown of about A$17m completed under A$34m non-dilutive facility
- Drawdown is 50% of committed amount; remainder available to 31 March 2027
- Option to lift total commitments to up to A$50m; no current plans to do so
- Company says funding covers ACTION3 Phase 3 and DMX-652 Phase 2 plans
- Five partners to date: A$81m upfront received; up to A$237m further milestones
About Dimerix (ASX:DXB)
Dimerix Limited is an ASX-listed clinical-stage biopharmaceutical company headquartered in Melbourne. It develops drug candidates for kidney disease, led by DMX-200 for focal segmental glomerulosclerosis and DMX-652 for acute kidney injury. It licenses its candidates to commercial partners for distribution in overseas markets.
Dimerix Limited (ASX:DXB) has completed the initial drawdown under its previously announced A$34 million non-dilutive funding facility, receiving gross proceeds of approximately A$17 million.
The drawdown represents 50% of the currently committed facility amount. The remaining A$17 million is available for draw-down at Dimerix's election until 31 March 2027, subject to facility terms. Under the facility's terms, Dimerix has the option to secure up to A$50m in total commitments on or before 31 March 2027, noting the Company currently has no plans to access this additional funding. Dimerix says the funding position is considered sufficient to complete currently planned activities, including delivery of the ACTION3 Phase 3 trial of DMX-200 and continued advancement of the Phase 2 trial of DMX-652, through existing cash reserves and the A$34 million via the binding Loan Agreements. The drawdown of the facility is anticipated to be repaid through existing future licensee milestone payment(s), potential new license fees and/or capital market access. Dimerix has secured five commercial partners across major markets, generating A$81 million in upfront payments received to date and creating the opportunity for a further A$237 million in development milestone payments ahead of commercial launch.
The release does not restate interest rate or security terms for the facility beyond referring to the prior announcement.
Source: Dimerix Limited (ASX:DXB), 23 September 2026. Summary content supplied by Digifin Pty Ltd.
News summary only, not financial advice. It does not consider your objectives, financial situation or needs.